Specialty pharmaceutical company focused on pediatric psychiatry. NextWave’s core product franchises are focused on fast onset and long acting liquid and chewable formulations of methylphenidate and clonidine, agents with well-established clinical activity in pediatric indications such as Attention Deficit Hyperactivity Disorder (ADHD), Autism, Tourette’s, and hypertension. In November 2012, NextWave was acquired by Pfizer.
NextWave Pharmaceuticals
![NextWave Pharmaceuticals](http://baycitycapital.com/wp-content/uploads/2014/04/portfolio-nextwave.jpg)